Alba Jimenez joined Flagship in 2022 as an Associate. In this role, she is part of a venture creation team developing the science, intellectual property, and business strategies that form the foundation of Flagship’s breakthrough bioplatform companies.
Alba earned her Ph.D. in Systems Biology from the Center for Genomic Regulation in Barcelona, where she applied in silico models to understand pattern formation during embryonic development. These models explain how regulatory circuits of genes drive complex spatial patterns and how mutations in gene circuits manifest in novel phenotypes, with implications in development and disease.
Her postdoctoral research at the Systems Biology Department at Harvard Medical School integrated theory with experiments to design drug therapies based on modeling the temporal dynamics of the tumor suppressor p53. In addition to her extensive scientific training, Alba holds an MBA from College des Ingenieurs.